Peripheral Artery Disease - China Drug Forecast and Market Analysis to 2024
In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.’s Zontivity (vorapaxar), AstraZeneca’s Brilinta (ticagrelor), and Bayer and Janssen’s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.
In 2014, the PAD therapeutics market in China was worth approximately $93.7m. Generic anticoagulant drugs, primarily warfarin, will suffer a negative CAGR of approximately 10.15% as Xarelto and generic rivaroxaban begin to encroach on warfarin’s stake in the PAD market.
Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in China including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in China from 2014-2024.
Analysis of the impact of key events as well the drivers and restraints affecting China PAD market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for PAD.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2014-2024 in China.